Asia Pacific Imiglucerase Market
- 2026 年市場規模
- USD 192.7 Mn
- 2033 年預估規模
- USD 262.1 Mn
- 年複合成長率 CAGR
- 4.5%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Asia Pacific Imiglucerase Market, By Strength (400 IU and 200 IU), By Brand (Cerezyme, Abcertin, and Others), By Geography (China, India, Singapore, Thailand, Vietnam, Malaysia, Philippines, Indonesia, Cambodia, and Rest of Asia Pacific)
報告摘要
The Asia Pacific imiglucerase market is estimated to be valued at USD 192.7 Mn in 2026 and is expected to reach USD 262.1 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033. The Asia Pacific imiglucerase market accounted for a significant portion of the rare diseases therapies sector, impelled by the rising demand for better treatments against Gaucher disease which is a lysosomal storage disorder resulting from the deficiency of the glucocerebrosidase enzyme. Imiglucerase which is predominantly available under the brand name of Cerezyme is the established enzyme replacement therapy (ERT) to treat the Type 1 and Type 3 Gaucher disease by replenishing the deficient enzyme activity and reducing glucocerebroside accumulation in affected organs.
In the Asia Pacific region, the market augmentation is being assisted by the increasing incidence rates of rare genetic conditions, early disease diagnoses through superior screening techniques, and extensive government support to the orphan drug for Gaucher’s treatment in various economies including Japan, China, South Korea, Australia, and India. Expanding healthcare facilities, elevated rates of patient-to-biologic-therapy access, along with rare disease management schemes continues to escalate the demand for imiglucerase across the region.
Market Dynamics
The Asia Pacific imiglucerase market is primarily driven by the improving diagnosis of Gaucher disease, increasing awareness of rare genetic disorders, and expanding access to specialized biologic therapies across the region. Government support through orphan drug policies, strengthening healthcare infrastructure, and collaborations between pharmaceutical companies and healthcare providers are further enhancing treatment availability in key markets such as Japan, China, South Korea, Australia, and India.
However, the growth of the market is limited by factors such as high cost of lifelong enzyme replacement therapy, limited reimbursement in several developing countries, and cold-chain distribution requirements continue to restrict market expansion. Nevertheless, there are abundant growth prospects due to factors such as increasing development of imiglucerase biosimilars, rising government initiatives for rare disease management, and expanding investment in rare disease research.
Key Features of the Study
• This report provides in-depth analysis of the Asia Pacific imiglucerase market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Asia Pacific imiglucerase market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amicus Therapeutics, Inc., Recordati S.p.A., Chiesi Farmaceutici S.p.A., Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., ISU ABXIS Co., Ltd., and Avesthagen Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Asia Pacific imiglucerase market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia Pacific imiglucerase market
Market Segmentation
• Strength Insights (Revenue, USD Mn, 2021 - 2033)
o 400 IU
o 200 IU
• Brand Insights (Revenue, USD Mn, 2021 - 2033)
o Cerezyme
o Abcertin
o Others
• Country Insights (Revenue, USD Mn, 2021 - 2033)
o China
o India
o Singapore
o Thailand
o Vietnam
o Malaysia
o Philippines
o Indonesia
o Cambodia
o Rest of Asia Pacific
• Key Players Insights
o Sanofi
o Takeda Pharmaceutical Company Limited
o Pfizer Inc.
o Amicus Therapeutics, Inc.
o Recordati S.p.A.
o Chiesi Farmaceutici S.p.A.
o Alexion Pharmaceuticals, Inc.
o BioMarin Pharmaceutical Inc.
o ISU ABXIS Co., Ltd.
o Avesthagen Limited
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Asia Pacific Imiglucerase Market, By Strength
Asia Pacific Imiglucerase Market, By Brand
Asia Pacific Imiglucerase Market, By Country
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Industry Trends
4. Asia Pacific Imiglucerase Market, By Strength, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o 400 IU
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o 200 IU
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Asia Pacific Imiglucerase Market, By Brand, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Cerezyme
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Abcertin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Asia Pacific Imiglucerase Market, By Country, 2021 - 2033, Value (USD Mn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
Country Trends
o China
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o India
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Singapore
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Thailand
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Vietnam
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Malaysia
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Philippines
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Indonesia
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Cambodia
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
o Rest of Asia Pacific
Introduction
Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Mn)
Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
7. Competitive Landscape
o Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Pfizer Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Amicus Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Recordati S.p.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Chiesi Farmaceutici S.p.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Alexion Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o BioMarin Pharmaceutical Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o ISU ABXIS Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Avesthagen Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
8. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
9. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on ‘Imiglucerase Market’– Asia Pacific forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們